



# Challenges in Understanding Pathways, Predicting Complexes, & Inferring Protein Function

Limsoon Wong




## Plan




- **Understanding Pathways**
  - Past successes
  - Towards more meaningful genes
  - Issues on pathway sources
- **Predicting Complexes**
  - Current approaches
  - Issues on network noise and density assumption
  - Benefits of network cleansing
- **Inferring Protein Function**
  - Guilt-by-association
  - When guilt-by-association fails

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

# Understanding Pathways




## Childhood Acute Lymphoblastic Leukemia




- **Major subtypes: T-ALL, E2A-PBX, TEL-AML, BCR-ABL, MLL genome rearrangements, Hyperdiploid>50**
- **The subtypes look similar**
- **Diff subtypes respond differently to same Tx**
- **Over-intensive Tx**
  - Development of secondary cancers
  - Reduction of IQ
- **Under-intensive Tx**
  - Relapse
- **Conventional diagnosis**
  - Immunophenotyping
  - Cytogenetics
  - Molecular diagnostics

⇒ Unavailable in developing countries




Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

## Patient Profiles & Treatment Costs



**Childhood ALL Patients Profile**




□ High 10%  
■ Inter 40%  
□ Low 50%

- **Treatment for childhood ALL over 2 yrs**
  - Intermediate intensity: US\$60k
  - Low intensity: US\$36k
  - High intensity: US\$72k
- **Treatment for relapse: US\$150k**
- **Cost for side-effects: Unquantified**
- **2000 new cases a year in ASEAN countries**

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

## Why not high/low intensity to everyone?



<ul style="list-style-type: none"> <li>• <b>High-intensity Tx</b> <ul style="list-style-type: none"> <li>– Over intensive for 90% of patients, thus a lot more side effects</li> <li>– US\$144m (US\$72k * 2000) for high-intensity tx</li> </ul> </li> </ul> <p>⇒ <b>Total US\$144m/yr plus un-quantified costs for dealing with side effects</b></p>	<ul style="list-style-type: none"> <li>• <b>Low-intensity Tx</b> <ul style="list-style-type: none"> <li>– Under intensive for 50% of patients, thus a lot more relapse</li> <li>– US\$72m (US\$36k * 2000) for low-intensity tx</li> <li>– US\$150m (US\$150k * 2000 * 50%) for relapse tx</li> </ul> </li> </ul> <p>⇒ <b>Total US\$222m/yr</b></p>
--	---

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Current Situation

- Intermediate intensity conventionally applied in ASEAN countries
- Over intensive for 50% of patients, thus more side effects
- Under intensive for 10% of patients, thus more relapse
- US\$120m (US\$60k \* 2000) for intermediate intensity tx
- US\$30m (US\$150k \* 2000 \* 10%) for relapse tx
- Total US\$150m/yr plus un-quantified costs for dealing with side effects

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Single-Test Platform of Microarray & Machine Learning

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Individual Gene Testing

**Fold Change**

$$FC_{ratio} = \frac{x_i}{y_i} \quad FC_{diff} = x_i - y_i$$

**T-test**

$$T_i = \frac{\bar{x}_i - \bar{y}_i}{s_i} \quad T_i = \frac{\bar{x}_i - \bar{y}_i}{s_i + s_o} \quad T_i = \frac{\bar{x}_i - \bar{y}_i}{\sqrt{Bs^2 + (1-B)s_i^2}}$$

x – Microarray value after drug  
 y – Microarray value before drug  
 i – Gene

x – Log2 value of treatment  
 y – Log2 value of control  
 s – Standard error  
 i – Gene

Golub et al, Science, 1999

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Diagnostic ALL BM samples (n=327)

Genes for class distinction (n=271)

E2A-PBX1 MLL T-ALL Hyperdiploid >50 BCR-ABL Novel TEL-AML1

Yeoh et al, Cancer Cell 2002

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Exploit Invariant Gene Expr Profiles

- Low intensity applied to 50% of patients
- Intermediate intensity to 40% of patients
- High intensity to 10% of patients
- ⇒ Reduced side effects
- ⇒ Reduced relapse
- ⇒ 75-80% cure rates
- US\$36m (US\$36k \* 2000 \* 50%) for low intensity
- US\$48m (US\$60k \* 2000 \* 40%) for intermediate intensity
- US\$14.4m (US\$72k \* 2000 \* 10%) for high intensity
- Total US\$98.4m/yr
- ⇒ Save US\$51.6m/yr

Yeoh et al, Cancer Cell 2002

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Diagnostic ALL BM samples (n=327)

Genes for class distinction (n=271)

E2A-PBX1 MLL T-ALL Hyperdiploid >50 BCR-ABL Novel TEL-AML1

But are all of these genes meaningful?

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Percentage of Overlapping Genes

- Low % of overlapping genes from diff expt in general
  - Prostate cancer
    - Lapointe et al, 2004
    - Singh et al, 2002
  - Lung cancer
    - Garber et al, 2001
    - Bhattacharjee et al, 2001
  - DMD
    - Haslett et al, 2002
    - Pescatori et al, 2007

Datasets	DEG	POG
Prostate Cancer	Top 10	0.30
	Top 50	0.14
	Top100	0.15
Lung Cancer	Top 10	0.00
	Top 50	0.20
	Top100	0.31
DMD	Top 10	0.20
	Top 50	0.42
	Top100	0.54

Zhang et al, Bioinformatics, 2009

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Gene Regulatory Circuits

- Each disease subtype has underlying cause
- There is a unifying biological theme for genes that are truly associated with a disease subtype

- Uncertainty in selected genes can be reduced by considering biological processes of the genes
- The unifying biological theme is basis for inferring the underlying cause of disease subtype

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Towards More Meaningful Genes

- ORA
  - Khatri et al
  - Genomics, 2002
- FCS
  - Pavlidis & Noble
  - PSB 2002
- GSEA
  - Subramanian et al
  - PNAS, 2005
- Pathway Express
  - Draghici et al
  - Genome Res, 2007

Gene Class Testing: Pathway Express

$$PF(g) = \log\left(\frac{1}{|g|}\right) + \frac{\sum_{i \in g} PF(i)}{\sum_{i \in N_u} PF(i)}$$

$$PF(g) = \Delta E(g) + \sum_{i \in g} \beta_i \frac{PF(i)}{N_u(i)}$$

Drelich et al, Genome Res, 2007

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Nasopharyngeal Carcinoma

- NPC patients respond differentially to CYC202

- Can we identify drug action pathways by these more sophisticated methods?

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

Futhermore,







All of these newer methods rely on gene group or pathway information.

But how good are the available sources of pathway information?

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong


### Low Comprehensiveness of Pathway Sources

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong



### Obstacles

Experimental method category*	interacting pairs
All: All methods	9347
A: Small scale Y2H	1861
A0: GY2H Uetz et al. (published results)	956
A1: GY2H Uetz et al. (unpublished results)	516
A2: GY2H Ito et al. (core)	798
A3: GY2H Ito et al. (all)	3658
B: Physical methods	71
C: Genetic methods	1052
D1: Biochemical, <i>in vitro</i>	614
D2: Biochemical, chromatography	648
E1: Immunological, direct	1025
E2: Immunological, indirect	34
2M: Two different methods	2360
3M: Three different methods	1212
4M: Four different methods	570



Sprinzak et al., *JMB*, 327:919-923, 2003

- Disagreement betw methods
- ⇒ High level of noise

- Cannot capture non-ball-like complexes
- ⇒ Clique merging? Relative density? Core-n-attachment?

### Measures that correlate with function homogeneity and localization coherence

- Two proteins participating in same biological process are more likely to interact
- Two proteins in the same cellular compartments are more likely to interact

➔

- CD-distance
- FS-Weight

CD-distance & FS-Weight: Based on concept that two proteins with many interaction partners in common are likely to be in same biological process & localize to the same compartment

### Iterated CD-Distance (Liu et al, GIW, 2008)

- Variant of CD-distance that penalizes proteins with few neighbors

$$wL(u,v) = \frac{2 |N_u \cap N_v|}{|N_u| + \lambda_u + |N_v| + \lambda_v}$$

$$\lambda_u = \max\{0, \frac{\sum_{x \in G} |N_x|}{|V|} - |N_u|\}, \lambda_v = \max\{0, \frac{\sum_{x \in G} |N_x|}{|V|} - |N_v|\}$$

- Suppose average degree is 4, then
  - Case 1:  $|N_u| = 1, |N_v| = 1, |N_u \cap N_v| = 1, wL(u,v) = 0.25$
  - Case 2:  $|N_u| = 10, |N_v| = 10, |N_u \cap N_v| = 10, wL(u,v) = 1$

### A thought...



$$wL(u,v) = \frac{2 |N_u \cap N_v|}{|N_u| + \lambda_u + |N_v| + \lambda_v}$$

- Weight of interaction reflects its reliability
- ⇒ Can we get better results if we use this weight to re-calculate the score of other interactions?

### Iterated CD-Distance (Liu et al, GIW, 2008)


- $wL^0(u,v) = 1$  if  $(u,v) \in G$ , otherwise  $wL^0(u,v) = 0$
- $wL^1(u,v) = \frac{|N_u \cap N_v| + |N_u \cap N_v|}{|N_u| + \lambda_u + |N_v| + \lambda_v}$
- $wL^k(u,v) = \frac{\sum_{x \in N_u \cap N_v} wL^{k-1}(u,x) + \sum_{x \in N_u \cap N_v} wL^{k-1}(v,x)}{\sum_{x \in N_u} wL^{k-1}(u,x) + \lambda_u^k + \sum_{x \in N_v} wL^{k-1}(v,x) + \lambda_v^k}$
- $\lambda_u^k = \max\{0, \frac{\sum_{x \in V} \sum_{y \in N_x} wL^{k-1}(x,y)}{|V|} - \sum_{x \in N_u} wL^{k-1}(u,x)\}$
- $\lambda_v^k = \max\{0, \frac{\sum_{x \in V} \sum_{y \in N_x} wL^{k-1}(x,y)}{|V|} - \sum_{x \in N_v} wL^{k-1}(v,x)\}$

### Identifying False Positive PPIs


- Iterated CD-distance is an improvement over previous measures for assessing PPI reliability

Liu et al, GIW 2008




Guangzhou, China, 4-6 June 2009

Copyright 2009 © Limsoon Wong




Guangzhou, China, 4-6 June 2009

Copyright 2009 © Limsoon Wong




Guangzhou, China, 4-6 June 2009

Copyright 2009 © Limsoon Wong




Guangzhou, China, 4-6 June 2009

Copyright 2009 © Limsoon Wong



Guangzhou, China, 4-6 June 2009


Copyright 2009 © Limsoon Wong




Guangzhou, China, 4-6 June 2009

Copyright 2009 © Limsoon Wong

# Inferring Protein Function



## Function Assignment to Protein Seq




```

SPSTNRKYPPLPVDKLEEEINRRMADDNKLFREEFNALPACFIQATCEAASKEENKEKNR
YVNLIPYDHSRVHLTPVEGVVDSYINASFINGYQEKNFIAAQGPKEETVDFWRMIWE
QNTATIVMVTNLKERKECKAQYWPDQGCWTYGNVRVSVEDVTVLVDYTVRKFICIQQVGD
VTNRKPQLRITQFHFTSWPDFGVFFPIGMLKFLKVKACNPFYAGAIIVHCSAGVGRTG
TFVVIDAMLDMHSEKVDVYGFVSRIRAQRQCMQVDMQYVFIYQALLEHYLGDTELE
VT
    
```

- How do we attempt to assign a function to a new protein sequence?

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Guilt by Association of Seq Similarity



Compare *T* with seqs of known function in a db

**Good Sequence Alignment**

- Good alignment usually has clusters of extensive matched positions
- ⇒ The two proteins are likely to be homologous

**Poor Sequence Alignment**

- Poor seq alignment shows few matched positions
- ⇒ The two proteins are not likely to be homologous


Assign to *T* same function as homologs

Discard this function as a candidate

Confirm with suitable wet experiments

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong


### What if there is no useful seq homolog?



- **Guilt by other types of association!**
  - Domain modeling (e.g., HMMPFAM)
  - Similarity of dissimilarities (e.g., SVM-PAIRWISE)
  - Similarity of phylogenetic profiles
  - Similarity of subcellular co-localization & other physico-chemico properties (e.g., PROTFUN)
  - Similarity of gene expression profiles
  - Similarity of protein-protein interaction partners
  - ...
  - Fusion of multiple types of info

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Similarity of Dissimilarities



Differences of "unknown" to other fruits are same as "apple" to other fruits


↓

"unknown" is an "apple"!

	Orange	Banana	...
Apple	Color = red vs orange Skin = smooth vs rough Size = small vs small Shape = round vs round	Color = red vs yellow Skin = smooth vs smooth Size = small vs small Shape = round vs oblong	...
Orange	Color = orange vs orange Skin = rough vs rough Size = small vs small Shape = round vs round	Color = orange vs yellow Skin = rough vs smooth Size = small vs small Shape = round vs oblong	...
Unknown	Color = red vs orange Skin = smooth vs rough Size = small vs small Shape = round vs round	Color = red vs yellow Skin = smooth vs smooth Size = small vs small Shape = round vs oblong	...

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### SVM-Pairwise Framework



**Training Data**

S1, S2, S3, ...

→ Feature Generation →

**Training Features**

S<sub>1</sub>, S<sub>2</sub>, S<sub>3</sub>, ...  
 S<sub>1</sub> f<sub>11</sub> f<sub>12</sub> f<sub>13</sub> ...  
 S<sub>2</sub> f<sub>21</sub> f<sub>22</sub> f<sub>23</sub> ...  
 S<sub>3</sub> f<sub>31</sub> f<sub>32</sub> f<sub>33</sub> ...  
 ... ..

*f<sub>11</sub> is the local alignment score between S<sub>1</sub> and S<sub>1</sub>*

→ Training →

**Support Vectors Machine**  
(Radial Basis Function Kernel)

↓

**Trained SVM Model**  
(Feature Weights)

**Testing Data**

T1, T2, T3, ...

→ Feature Generation →

**Testing Features**

T<sub>1</sub>, S<sub>1</sub>, S<sub>2</sub>, S<sub>3</sub>, ...  
 T<sub>1</sub> f<sub>11</sub> f<sub>12</sub> f<sub>13</sub> ...  
 T<sub>2</sub> f<sub>21</sub> f<sub>22</sub> f<sub>23</sub> ...  
 T<sub>3</sub> f<sub>31</sub> f<sub>32</sub> f<sub>33</sub> ...  
 ... ..

*f<sub>11</sub> is the local alignment score between T<sub>1</sub> and S<sub>1</sub>*

→ Classification →






**RBF Kernel**

↓

**Discriminant Scores**

Image credit: Kenny Chua

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong



### Functional Similarity Estimate: FS-Weighted Measure

- FS-weighted measure**

$$S(u, v) = \frac{2|N_u \cap N_v|}{|N_u - N_v| + 2|N_u \cap N_v|} \times \frac{2|N_u \cap N_v|}{|N_v - N_u| + 2|N_u \cap N_v|}$$

- $N_k$  is the set of interacting partners of  $k$
- Greater weight given to similarity

⇒ Rewriting this as

$$S(u, v) = \frac{2X}{2X + Y} \times \frac{2X}{2X + Z}$$

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong



### Functional Similarity Estimate: FS-Weighted Measure with Reliability

- Take reliability into consideration when computing FS-weighted measure:

$$S_k(u, v) = \frac{2 \sum_{w \in (N_u \cap N_v)} r_{u,w} r_{v,w}}{\left( \sum_{w \in N_u - N_v} r_{u,w} + \sum_{w \in (N_u \cap N_v)} r_{u,w} (1 - r_{v,w}) \right) + 2 \sum_{w \in (N_u \cap N_v)} r_{u,w} r_{v,w}} \times \frac{2 \sum_{w \in (N_u \cap N_v)} r_{u,w} r_{v,w}}{\left( \sum_{w \in N_v - N_u} r_{v,w} + \sum_{w \in (N_u \cap N_v)} r_{v,w} (1 - r_{u,w}) \right) + 2 \sum_{w \in (N_u \cap N_v)} r_{u,w} r_{v,w}}$$

- $N_k$  is the set of interacting partners of  $k$
- $r_{u,w}$  is reliability weight of interaction between  $u$  and  $v$

⇒ Rewriting

$$S(u, v) = \frac{2X}{2X + Y} \times \frac{2X}{2X + Z}$$

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Improvement to Prediction Power by Majority Voting

Considering only neighbours w/ FS weight > 0.2

Chua et al, Bioinformatics, 2006

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Use L1 & L2 Neighbours for Prediction

- FS-weighted Average

$$f_x(u) = \frac{1}{Z} \left[ \lambda r_{int} \pi_x + \sum_{v \in N_u} \left( S_{TR}(u, v) \delta(v, x) + \sum_{w \in N_v} S_{TR}(u, w) \delta(w, x) \right) \right]$$

- $r_{int}$  is fraction of all interaction pairs sharing function
- $\lambda$  is weight of contribution of background freq
- $\delta(k, x) = 1$  if  $k$  has function  $x$ , 0 otherwise
- $N_k$  is the set of interacting partners of  $k$
- $\pi_x$  is freq of function  $x$  in the dataset
- $Z$  is sum of all weights

$$Z = 1 + \sum_{v \in N_u} \left( S_{TR}(u, v) + \sum_{w \in N_v} S_{TR}(u, w) \right)$$

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Performance of FS-Weighted Averaging

- LOOCV comparison with Neighbour Counting, Chi-Square, PRODISTIN

Chua et al, Bioinformatics, 2006

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Combining multiple data sources leads to further improvement.


But there is still a long way to go...

Chua et al, Bioinformatics, 2007

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

### Closing Remarks


## What Have We Learned?



- **Problems**
  - Gene expression analysis
  - Protein complex prediction
  - Protein function inference
- **Trends**
  - Algorithms driven by reasonable hypotheses
  - Hypotheses extracted by datamining & statistics

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

## What we are planning next...



- **Lipid biology**
  - How to expand PPI networks with more info?
  - How to use it to infer proteins & complexes involved in lipid metabolism?
- **Drug response & escape**
  - How to augment PPI networks of microbacteria?
  - How to infer drug-response/escape routes?
  - How to cut off drug-escape routes?

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong


## Acknowledgements



- Jinyan Li
- Huiqing Liu
- Difeng Dong
- Donny Soh
- Hon Nian Chua
- Guimei Liu

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong

## References



- D Soh, et al. Enabling More Sophisticated Gene Expression Analysis for Understanding Diseases and Optimizing Treatments. *ACM SIGKDD Explorations*, 9(1):3-14, 2007
- G Liu, et al. Assessing and Predicting Protein Interactions Using Both Local and Global Network Topological Metrics. *Proc GIW 2008*
- G Liu, et al. Complex Discovery from Weighted PPI Networks. *Bioinformatics*, to appear
- HN Chua, et al. Exploiting indirect neighbours and topological weight to predict protein function from protein-protein interactions. *Bioinformatics*, 22:1623-1630, 2006
- HN Chua, et al. An efficient strategy for extensive integration of diverse biological data for protein function prediction. *Bioinformatics*, 23(24):3364-3373, 2007

Guangzhou, China, 4-6 June 2009 Copyright 2009 © Limsoon Wong